Icure Pharmaceutical Incorporation (175250) — Capital Reinvestment Ratio
Latest as of June 2020:
38.07x
Icure Pharmaceutical Incorporation (175250) has a Capital Reinvestment Ratio of 38.07x as of June 2020, meaning it reinvests 38% of its operating cash flow (₩195.44 Million) in capital expenditures (₩7.44 Billion). See 175250 free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
38.07x
Capex / Operating Cash Flow
Operating Cash Flow
₩195.44 Million
KRW
Capital Expenditures
₩7.44 Billion
KRW
Data as of
Jun 2020
Most recent filing
Icure Pharmaceutical Incorporation Capital Reinvestment Ratio (2017–2017)
This chart tracks Icure Pharmaceutical Incorporation's Capital Reinvestment Ratio across 1 annual periods.
Annual Capital Reinvestment Ratio for Icure Pharmaceutical Incorporation (2017–2017)
Year-by-year Capital Reinvestment Ratio for Icure Pharmaceutical Incorporation from 2017 to 2017. For live market cap and broader valuation context, see 175250 market cap overview.
| Year | Reinvestment Ratio | Operating CF (KRW) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2017 | 9.02x | ₩1.12 Billion | ₩10.10 Billion | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow